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Conclusions: This study shows that the radiochromic silicone 
based 3D dosimeter is dose-rate independent with 0.25 % 
(w/w) LMG and 1 % (w/w) chloroform. This greatly enhances 
its usability in clinical environments, however, the decreased 
stability of the dosimeter due to the increased LMG 
concentration must be carefully considered. 
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Purpose/Objective: The new DMI MV imaging panel with 
Eclipse/Aria permits measurements of FFF integrated images 
and configuration of the Portal Dosimetry algorithm ('PDIP') 
for QA of IMRT and Rapid Arc ('RA') treatment plans. This 
study evaluates the commissioning procedure for the Portal 
Dosimetry ('PD') system for FFF energies and the resulting 
implementation for IMRT and RA pre-treatment QA. To 
evaluate the accuracy and performance of the PD system, 
measurements were also performed using the new Octavius 
1500 system.  
Materials and Methods: A Varian TrueBeam equipped with 
HD-MLC and the new DMI imager was used to configure and 
evaluate the PDIP algorithm. The DMI panel has high 
resolution imaging capabilities and together with the new 
version of Eclipse/Aria (V.13) allows for configuration of the 
PDIP for use with FFF energies. The PDIP was configured for 
use at 100 cm SDD by measuring the imager output factors 
and an ideal fluence provided by Varian. The 6 MV was used 
as the standard for performance evaluation of the imager and 
PD configuration for the 6 and 10 FFF energies. Measured 
output factors, open fields, and test complex fluences were 
compared to those predicted by the PDIP to validate the 
configuration. Test IMRT and RA plans were measured and 
analyzed using the PD software. A further evaluation of the 
PD was performed by repeating fluence and test plan 
measurements on the new Octavius 1500 array system. The 
array was commissioned with solid water plates and also 
inserted in the cylindrical rotational polystyrene phantom 
(Octavius 4D). The latter setup was used with an inclinometer 
to assess the agreement between measured and planned 
doses and for comparison with results obtained on the PD. 
Volumetric (3D) and planar (2D) gamma analysis are available 
for the reconstructed dose volume to check the dose in a 
volume or in a plane, respectively. All fluences and test plans 
were analyzed using the gamma criteria of 2%-2mm and 10% 
dose threshold. 
Results: The PDIP algorithm showed agreement within <1% 
between the measured and calculated output factors for 6 
MV and 6 FFF and within <1.5% for 10 FFF. The open field and 
test fluences on the PD system resulted in a gamma passing 
criteria >99.0% and >97.2%, respectively. The test IMRT plans 
resulted in gamma analysis >99.2% (<γ>=99.7±0.4%) on the 
PD, >96.5% (<γ>=98.0±1.6%) on the Octavius with 2D analysis, 
and >97.1% (<γ>=97.5±0.5%) on the Octavius with 3D analysis. 
The test RA plans resulted in a gamma analysis >97.0% 
(<γ>=99.0±1.2%) on the PD and >97.8% (<γ>=99.0±0.7%) on 
the Octavius with 3D analysis (Figure: 10FFF RA;Table: RA 
analysis).  
 
 
Conclusions: The Portal Dosimetry system for the TrueBeam 
with DMI imager can be used for IMRT and RA pretreatment 
QA verification for FFF energies. The results obtained with 
the PD were comparable to those obtained with direct 
measurement equipment such as the PTW Octavius 1500. The 
PD system has higher resolution and measurement points 
which could have resulted in a slightly higher gamma analysis 
passing rate when compared to the Octavius. 
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Purpose/Objective: This work evaluates the potential of the 
new aS1200 EPID (Varian Medical Systems) for pre-treatment 
and in vivo dosimetry (IVD) applications. 
Materials and Methods: Measurements were performed using 
one aS1200 and an older aS1000 unit, both mounted on 
matched TrueBeam linacs. Comparative specifications are in 
Table 1. 
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All images were acquired at 100 cm SID using the integrating 
dosimetry mode at the maximum available dose rate: 600 
MU/min at 6 and 10 MV for both EPIDs, and 1400 MU/min at 6 
MV FFF and 2400 MU/min at 10 MV FFF for the aS1200. 
Different fields were delivered from 3×3 cm2 up to the 
maximum accommodated by the panel to verify the CAX 
signal increased with field size. Dose linearity was 
investigated by irradiating 10×10 cm2 fields from 1 to 100 MU 
and considering the signal on the CAX. Ghosting was assessed 
by delivering three 100 MU fields: a 10×10 cm2, followed 
immediately by a 20×20 cm2 then a second 10×10 cm2 and 
measuring residual signal ±7.5 cm from the CAX. The ratio of 
signals ±3 cm vertically from the CAX was calculated for 
fields > 8×8 cm2 to determine the impact of backscatter. The 
Modulation Transfer Function (MTF) was determined at each 
energy from images of an opaque angled edge. All image 
analysis was performed using IQWorks. 
A number of IMRT and VMAT plans were verified pre-
treatment using Portal Dosimetry (PD, Varian Medical 
Systems) and in vivo using Dosimetry Check (DC, Math 
Resolutions LLC). 
Results: Saturation was not evident and dose linearity was 
within ±1.0% at all energies / dose-rates for both detectors. 
Signal lag (Fig 1a) was <1.5% for the aS1000 and <0.6% for the 
aS1200. 
Differential backscatter (Fig 1b) from the aS1000 support arm 
increases with field size up to a maximum of 2.5%. On the 
aS1200 it is negligible (<0.5%) and independent of field size 
due to additional shielding material attached to the back of 
the panel. However, the increased backscatter overall results 
in marginally poorer MTF at lower spatial frequencies (Fig 
1c). 
All patient plans evaluated using PD yielded gamma pass 
rates (gamma < 1) of 100% when using criteria of 3%/3mm 
and >99.5% using criteria of 2%/2mm. Test plans with 2.5 mm 
MLC leaf errors required 2%/2mm to be detected on the 
aS1200 compared with 3%/3mm on the aS1000. This may be 
due to the higher bit depth and lower signal lag. 
IVD was successfully performed for large field, multi arc 
VMAT plans, with gamma pass rates > 90% at 5%/3mm for 
irradiated areas of side up to 26 cm at 150 cm SID. 
 
 
Conclusions: The aS1200 improves on the aS1000 as a 
dosimeter, overcoming limitations of the previous device and 
permitting more accurate measurements. 
Performance was found to be superior to the previous 
generation detector in every metric, except for a small 
reduction in MTF at low spatial frequencies which is not 
clinically significant. In particular, the impact of support arm 
backscatter is negligible and the ability to image large field 
and FFF beams allows the new EPID to be applied to a wider 
range of pre-treatment and IVD imaging scenarios. 
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Purpose/Objective: Polymer gel dosimeters are tissue 
equivalent materials fabricated from radiation sensitive 
chemicals which, upon irradiation, polymerize as a function 
of absorbed radiation dose. Gel dosimeters can uniquely 
record the radiation dose distribution in three-dimensions 
(3D). Such dose distribution can be subsequently imaged by 
MRI, optical computerized tomography (OCT), x-ray CT or 
ultrasound. We describe the fabrication and physical 
properties of a new gel with favorable characteristics for the 
3D Gel dosimetry applications when compared to the existing 
gel compositions. 
Materials and Methods: Three novel normoxic hydroxyl-
ethyl-methacrylate (HEMAGAT) gel variations were fabricated 
using formulation given in Table 3 (Fig.1). Its properties 
(absorbance and stability) were compared to three Acryl-
amid (PAGAT) polymer gels designed using formulation given 
in Table 1 (Fig.1), as well as four N-isopropyl-acryl-amide 
(NIPAMGAT) gels (Table 2, Fig.1).  
Each sample vial filled with gel was placed in a water 
phantom, and irradiated using a 6 MV photon beam from a 
Varian medical linear accelerator to various doses. Samples 
were transferred back to refrigerator and kept for 24 hours 
prior to absorption measurements.  
Absorption spectra of irradiated gel samples were measured 
in a range from 350 - 650 nm using UV/VIS 
spectrophotometer, model Lambda 850, from Perkin-Elmer, 
USA. Three samples at each absorbed dose were measured, 
but no significant differences in their characteristics were 
found during measurements. To test the post-irradiation 
stability of polymerized gels, we were sampling the gel 
response at two dose levels (6 and 15 Gy) once a day for 
seven days. 
Results: Figure 1 compares the dose response (absorbance 
sampled at 500 nm) for the three gel models studied. The 
first two gel models deviate from linear behavior at doses 
well below 20 Gy, while the novel HEMAGAT gel model 
retains its linear behavior even at doses of up to 30 Gy. The 
highest sensitivity of the new gel model was exhibited by the 
first chemical variation containing 4 w/w% of HEMA (2-
hydroxy-ethyl-methacrylate). Results demonstrated that the 
stability of novel HEMAGAT gel depend strongly on 
concentration of hydroquinone (HQ). For gel variations 
presented here (Fig.1, Table 3) results show no change (less 
than ±2%; 1σ) in the sample responses of up to seven days 
after irradiation. 
Conclusions: All three variations of the new gel composition 
described exhibit favorable linear behavior dose response in a 
